Cystic Fibrosis Blood Neutrophils (MUCO-PNN)
Cystic Fibrosis
About this trial
This is an interventional basic science trial for Cystic Fibrosis focused on measuring Blood neutrophils, Pseudomonas aeruginosa, Cystic fibrosis, CFTR modulators, respiratory exacerbation, airway chronic infection
Eligibility Criteria
Inclusion Criteria:
- Patient over the age of 18 who is not under legal protection
Patients with CF according to the diagnostic criteria of the Cystic Fibrosis Foundation including:
- 15 patients with severe mutation but not chronically infected with PA and not treated with lumacaftor / ivacaftor
- 15 patients homozygous phe508del, chronically infected with PA and not treated with lumacaftor / ivacaftor
- 15 patients homozygous phe508del, chronically infected with PA and treated with lumacaftor / ivacaftor
- 15 hospitalized patients for respiratory exacerbation
- 40 patients initiating Ivacaftor-Tezacaftor-Elexacaftor treatment.
- No change in baseline treatment for 15 days (including antibiotic treatment).
- Patient affiliated to a social security system
- Free, informed and written consent, dated and signed by the patient and the investigator, at the latest on the day of inclusion and before any action required by the study.
Exclusion Criteria:
- Informed consent impossible to obtain
- Involvement in an interventional research protocol in the previous 3 months if exclusion directive was given in this protocol.
Sites / Locations
- Cochin hospital, AP-HPRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Stable state
Starting Ivacaftor-Tezacaftor-Elexacaftor
Exacerbation
45 adult cystic fibrosis patients followed in the respiratory medicine department of Cochin hospital, paris, France: With severe cftr mutations With or without PA chronic infection Treated or not with Ivacaftor-Lumacaftor
40 adult cystic fibrosis patients followed in the respiratory medicine department of Cochin hospital, paris, France: With at least one severe cftr mutation With or without PA chronic infection Initiating Ivacaftor-Tezacaftor-Elexacaftor
15 adult cystic fibrosis patients followed in the respiratory medicine department of Cochin hospital, paris, France and hospitalized for respiratory exacerbation